Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Average R

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Rating) have been assigned an average recommendation of “Moderate Buy” from the nineteen ratings firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and fifteen have issued a buy recommendation on […]

Related Keywords

Robertw Baird , Glenn Goddard , Laura Sepp Lorenzino , Intellia Therapeutics Inc , Securities Exchange Commission , Nasdaq , Vanguard Group Inc , Blackrock Inc , Investment Management , Cantor Fitzgerald , Intellia Therapeutics , Get Rating , Chardan Capital , Exchange Commission , State Street Corp , Street Corp , Intellia Therapeutics Daily , Nasdaq Ntla , Intla , Medical , Ratings , Consensus ,

© 2025 Vimarsana